Company: STAA
Filing Date: 2025-08-05
Form Type: DEFA14A
Source: 0001193125-25-173098
Chunk: 27

Company: STAAR SURGICAL CO
Filing Date: 2025-08-05
Form: DEFA14A
Chunk 27
---

(f) As of the date of this Agreement, there are no outstanding or unresolved comments in
comment letters received from the SEC with respect to the Company SEC Documents. To the knowledge of the Company, (i) none of the Company SEC Documents is the subject of ongoing SEC review and (ii) there are no inquiries or investigations
by the SEC or any internal investigations pending or threatened, in each case, regarding any accounting practices of the Company. The Company has made available to Parent all correspondence between the Company, on the one hand, and the SEC, on the
other hand, since January 1, 2023 through the date hereof.

(g) The proxy statement of the Company to be filed with the SEC in
connection with the Merger and any amendments or supplements thereto (the “”), when filed, distributed or otherwise disseminated to the Company’s stockholders, as applicable, and at the time of the Stockholder
Meeting, will comply as to form in all material respects with the applicable requirements of the Exchange Act. The Proxy Statement, at the time of the filing of such Proxy Statement or any supplement or amendment thereto with the SEC, at the time
such Proxy Statement or any supplement or amendment is first distributed or otherwise disseminated to the Company’s stockholders, and at the time of the Stockholder Meeting, will not contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, the Company makes no
representation with respect to statements made or incorporated by reference therein based on information supplied by or on behalf of Parent, Merger Sub or their Affiliates for inclusion or incorporation by reference in the Proxy Statement.

3.5Absence of Changes; No Material Adverse Effect.

(a) Since December 27, 2024 to the date of this Agreement, except for discussions, negotiations and activities related to this Agreement
and the Transactions or any similar alternative transactions, the Acquired Corporations have operated in all material respects in the ordinary course of business.

(b) Since December 27, 2024 to the date of this Agreement, there has not occurred any event, occurrence, circumstance, change or effect
that, individually or when taken together with all other events, occurrences, circumstances, changes or effects, has had or would reasonably be expected to have, a Material Adverse Effect.

(c)